Evaluation of time in therapeutic range in anticoagulated patients: A single-center, retrospective, observational study

BMC Research Notes

Volumn 7, Issue 1, 2014, Pages

  Caldeira, Daniel ^a,b,c   Cruz, Inês ^a   Morgado, Gonçalo ^a   Stuart, Bruno ^a   Gomes, Catarina ^a   Martins, Cristina ^a   João, Isabel ^a   Pereira, Hélder ^a  

^a HOSPITAL GARCIA DE ORTA   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Anticoagulation quality; TTR; Vitamin K antagonist; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; WARFARIN;

AGED; ATRIAL FIBRILLATION; FEMALE; FOLLOW UP; HEMORRHAGE; HOSPITAL; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; VENOUS THROMBOEMBOLISM; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HOSPITALS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; RETROSPECTIVE STUDIES; RISK FACTORS; RIVAROXABAN; TIME FACTORS; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84925303218     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-7-891     Document Type: Article

References (21)

1. Wysowski DK, Nourjah P, Swartz L: Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007, 167:1414-1419.
2. Odén A, Fahlén M, Hart RG: Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res 2006, 117:493-499.
3. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW: Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007, 167:239-245.
4. You JH: Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation - a cost-effectiveness analysis. J Gen Intern Med 2014, 29:438-446.
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
6. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ, RE-LY investigators: Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010, 376:975-983.
7. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu Y: Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008, 1:84-91.
8. Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, Aikens TH, Yang S, Reilly PA, Lip GY, Yusuf S, RE-LY Steering Committee and Investigators: Dabigatran and warfarin in vitamin K antagonist-naive and-experienced cohorts with atrial fibrillation. Circulation 2010, 122:2246-2253.
9. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E: A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993, 69:236-239.
10. Rose AJ, Ozonoff A, Henault LE, Hylek EM: Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost 2008, 6:1647-1654.
11. Menzin J, Boulanger L, Hauch O, Friedman M, Marple CB, Wygant G, Hurley JS, Pezzella S, Kaatz S: Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. Ann Pharmacother 2005, 39:446-451.
12. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY: A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138:1093-1100.
13. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP: Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011, 106:968-977.
14. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S, ACTIVE W Investigators: Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008, 118:2029-2037.
15. Apostolakis S, Sullivan RM, Olshansky B, Lip GY: Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 2013, 144:1555-1563.
16. Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, Halperin JL, Becker RC, Breithardt G, Hankey GJ, Hacke W, Nessel CC, Patel MR, Califf RM, Fox KA, ROCKET AF Investigators: Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc 2013, 2:e000067.
17. Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, et al: Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 2013, 127:2166-2176.
18. Baker WL, Cios DA, Sander SD, Coleman CI: Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009, 15:244-252.
19. Schmitt L, Speckman J, Ansell J: Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-intherapeutic range. J Thromb Thrombolysis 2003, 15:213-216.
20. Cruz E, Campos M: Anticoagulation clinics, present situation and future perspectives. Rev Port Cardiol 2012, 31(Suppl 1):51-57.
21. Ferreira F, Antunes E, Neves RC, Farias F, Malveiro P, Choon H, Galrinho A, Cruz FR: INR telemonitoring: efficacy and safety of a telemonitoring program in 453 patients. Acta Med Port 2012, 25:297-300.